Akero Therapeutics, Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. The Company’s lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase 2b clinical trials in patients with biopsy-confirmed NASH: a long-term follow-up period for the HARMONY study in patients with pre-cirrhotic NASH (F2-F3 fibrosis), for which it reported results after 24 weeks of treatment, and the SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis, compensated). Its EFX program focused on patients with cirrhotic NASH (F4, compensated), in Phase 2b clinical trial.
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
|Date||Event description||Earnings per|
|May 15, 2023||Q1 2023 Earnings Release||-$0.55||-$0.80 to -$0.58||-$0.74|
|March 17, 2023||Q4 2022 Earnings Release||-$0.49||-$0.89 to -$0.67||-$0.93|
|November 4, 2022||Q3 2022 Earnings Release||-$0.92||-$0.81 to -$0.64||-$0.70|
|August 4, 2022||Q2 2022 Earnings Release||-$0.77||-$1.04 to -$0.72||-$0.83|
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.